Corvus Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, CRVS, Corvus Pharmaceuticals Inc, priceseries

Corvus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
1.52
Close
1.56
High
1.66
Low
1.52
Previous Close
1.53
Daily Price Gain
0.03
YTD High
2.51
YTD High Date
Jan 3, 2022
YTD Low
1.52
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.92
YTD Gain
-37.10%
52 Week High
9.54
52 Week High Date
Sep 21, 2021
52 Week Low
1.52
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-1.30
52 Week Gain
-45.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
15.57
Apr 4. 2017
20.09
19 Trading Days
29.00%
Link
LONG
May 11. 2017
10.11
May 30. 2017
10.71
12 Trading Days
5.98%
Link
LONG
Aug 23. 2017
13.00
Sep 20. 2017
16.39
19 Trading Days
26.06%
Link
LONG
Dec 22. 2017
10.55
Dec 27. 2017
11.12
2 Trading Days
5.38%
Link
LONG
Mar 6. 2018
9.04
Apr 5. 2018
10.95
21 Trading Days
21.16%
Link
LONG
May 17. 2018
10.07
Jun 4. 2018
11.92
11 Trading Days
18.39%
Link
LONG
Apr 18. 2019
3.95
Apr 30. 2019
4.29
7 Trading Days
8.49%
Link
LONG
Jun 28. 2019
3.74
Jul 16. 2019
5.47
11 Trading Days
46.38%
Link
LONG
Sep 9. 2019
3.87
Sep 12. 2019
4.17
3 Trading Days
7.62%
Link
LONG
Oct 10. 2019
2.90
Oct 25. 2019
3.21
11 Trading Days
10.85%
Link
LONG
Mar 25. 2020
2.23
Mar 30. 2020
2.38
3 Trading Days
6.84%
Link
LONG
May 5. 2020
3.03
May 28. 2020
3.68
16 Trading Days
21.43%
Link
LONG
Feb 8. 2021
4.28
Feb 10. 2021
4.50
2 Trading Days
5.02%
Link
LONG
Aug 23. 2021
2.05
Sep 10. 2021
2.49
13 Trading Days
21.58%
Link
LONG
Sep 17. 2021
5.32
Sep 29. 2021
6.12
8 Trading Days
15.08%
Link
LONG
Feb 4. 2022
1.83
Feb 11. 2022
1.93
5 Trading Days
5.59%
Link
Company Information
Stock Symbol
CRVS
Exchange
NasdaqGM
Company URL
http://www.corvuspharma.com
Company Phone
(650) 900-4520
CEO
Richard A. Miller
Headquarters
California
Business Address
863 MITTEN ROAD, SUITE 102, BURLINGAME, CA 94010
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001626971
About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel immuno-oncology therapies designed to harness the immune system to attack cancer cells. Its products include CPE-444, an orally administered antagonist of the adenosine A2A receptor; Adenosine production inhibitor; Adenosine A2B antagonist; and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. The company was founded by Richard A. Miller, Leiv Lea, and Joseph J. Buggy in January 27, 2014 and is headquartered in Burlingame, CA.

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading